We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




World’s First AI-Powered Tool to Transform Type 1 Diabetes Diagnosis and Treatment

By LabMedica International staff writers
Posted on 09 Jun 2025

For years, testing for Type 1 Diabetes (T1D) has relied on symptoms and biomarkers that typically become evident only at the disease’s onset, making early detection difficult. More...

This is particularly concerning because early-onset T1D, especially before age 10, tends to be more aggressive and is linked to a reduction in life expectancy of up to 16 years. Accurately forecasting disease progression could allow clinicians to act earlier. Now, an artificial intelligence (AI)-powered tool is showing promise in assessing T1D risk and predicting how patients will respond to treatments, potentially reshaping how the disease is identified and managed.

An international research team led by Western Sydney University (Penrith, NSW, Australia) has created a novel risk score based on microRNAs—tiny RNA molecules found in blood—that can effectively track the evolving risk of developing T1D. These same microRNA markers also predicted early responses to treatments such as islet cell transplantation and the drug imatinib. Published in Nature Medicine, the study evaluated molecular data from 5,983 samples collected from participants in Australia, Canada, Denmark, Hong Kong SAR China, India, New Zealand, and the USA. This led to the development of a Dynamic Risk Score (DRS4C) capable of identifying individuals as either having or not having T1D.

Using AI, the team further refined the risk score, which was validated with data from 662 additional participants. Remarkably, just one hour after therapy, the tool could predict which T1D patients would remain insulin-independent. The same microRNA profile also distinguished between responders and non-responders to the T1D drug therapy before treatment even began. Aside from gauging T1D risk and treatment effectiveness, the risk score may also help differentiate between T1D and Type 2 Diabetes (T2D)—a diagnostic challenge, especially in adults. A sub-analysis highlighted the tool’s potential to classify T2D individuals apart from those with T1D, an area the researchers plan to explore further, as many adult-onset T1D cases are often misdiagnosed as T2D.

“Genetic markers identify lifelong risk, it’s like knowing you live in a flood zone, but dynamic risk scores offer a real-time check on the rising water levels; it reflects current risk rather than a lifelong sentence, allowing for timely and adaptive monitoring without stigma,” said lead researcher Dr. Mugdha Joglekar at the Western Sydney University.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Mini Vortex Mixer
Vornado
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.